WVE Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2023-06-26 | 2022 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 617,900 | 0 | 0 | 461,900 | 22,977 | 2,667,997 |
| 2023-06-26 | 2021 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 597,000 | 0 | 0 | 388,100 | 9,510 | 3,892,610 |
| 2023-06-26 | 2022 | Chandra Vargeese, Ph.D. Chief Technology Officer, Head of Platform Discovery Sciences | 459,540 | 0 | 0 | 237,800 | 12,714 | 1,231,794 |
| 2023-06-26 | 2021 | Chandra Vargeese, Ph.D. Chief Technology Officer, Head of Platform Discovery Sciences | 444,000 | 0 | 0 | 199,800 | 12,264 | 1,511,564 |
| 2023-06-26 | 2022 | Kyle Moran, CFA | 439,875 | 0 | 0 | 227,600 | 10,392 | 1,148,790 |
| 2022-06-29 | 2020 | Chandra Vargeese, Ph.D. Chief Technology Officer, Head of Platform Discovery Sciences | 434,520 | 0 | 0 | 173,808 | 10,872 | 795,586 |
| 2022-06-29 | 2021 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 597,000 | 0 | 0 | 388,100 | 9,510 | 3,892,610 |
| 2022-06-29 | 2020 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 578,977 | 0 | 0 | 376,335 | 6,154 | 1,270,141 |
| 2022-06-29 | 2021 | Michael Panzara, M.D., MPH Chief Medical Officer, Head of Therapeutics Discovery and Development | 471,000 | 0 | 0 | 212,000 | 9,942 | 1,548,442 |
| 2022-06-29 | 2020 | Michael Panzara, M.D., MPH Chief Medical Officer, Head of Therapeutics Discovery and Development | 460,860 | 0 | 0 | 184,344 | 9,792 | 831,382 |
| 2022-06-29 | 2021 | Chandra Vargeese, Ph.D. Chief Technology Officer, Head of Platform Discovery Sciences | 444,000 | 0 | 0 | 199,800 | 12,264 | 1,511,564 |
| 2021-06-28 | 2019 | Chandra Vargeese, Ph.D. Chief Technology Officer | 426,000 | 0 | 0 | 127,800 | 10,722 | 1,239,522 |
| 2021-06-28 | 2020 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 578,977 | 0 | 0 | 376,335 | 6,154 | 1,270,141 |
| 2021-06-28 | 2019 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 578,977 | 0 | 0 | 282,251 | 20,298 | 3,581,526 |
| 2021-06-28 | 2020 | Michael Panzara, M.D., MPH Chief Medical Officer, Head of Therapeutics Discovery and Development | 460,860 | 0 | 0 | 184,344 | 9,792 | 831,382 |
| 2021-06-28 | 2019 | Michael Panzara, M.D., MPH Chief Medical Officer, Head of Therapeutics Discovery and Development | 451,815 | 0 | 0 | 135,545 | 9,642 | 1,272,002 |
| 2021-06-28 | 2020 | Chandra Vargeese, Ph.D. Chief Technology Officer | 434,520 | 0 | 0 | 173,808 | 10,872 | 795,586 |
| 2020-06-26 | 2017 | Chandra Vargeese, Ph.D. Chief Technology Officer | 350,000 | 0 | 0 | 154,000 | 7,380 | 1,157,264 |
| 2020-06-26 | 2018 | Keith C. Regnante Former Chief Financial Officer | 350,000 | 0 | 0 | 142,800 | 9,060 | 1,691,020 |
| 2020-06-26 | 2019 | Keith C. Regnante Former Chief Financial Officer | 362,250 | 0 | 0 | 108,675 | 9,642 | 1,088,067 |
| 2020-06-26 | 2017 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 515,300 | 0 | 0 | 283,400 | 528 | 3,196,645 |
| 2020-06-26 | 2018 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 541,100 | 0 | 0 | 303,557 | 9,983 | 5,839,966 |
| 2020-06-26 | 2017 | Keith C. Regnante Former Chief Financial Officer | 327,400 | 0 | 0 | 144,100 | 6,136 | 761,847 |
| 2020-06-26 | 2019 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 578,977 | 0 | 0 | 282,251 | 20,298 | 3,581,526 |
| 2020-06-26 | 2019 | Mark Baldry | 173,493 | 80,000 | 0 | 52,048 | 177,956 | 1,554,827 |
| 2020-06-26 | 2019 | Michael Panzara, M.D., MPH Chief Medical Officer | 451,815 | 0 | 0 | 135,545 | 9,642 | 1,272,002 |
| 2020-06-26 | 2018 | Michael Panzara, M.D., MPH Chief Medical Officer | 430,300 | 0 | 0 | 175,562 | 9,492 | 2,216,147 |
| 2020-06-26 | 2019 | Chandra Vargeese, Ph.D. Chief Technology Officer | 426,000 | 0 | 0 | 127,800 | 10,722 | 1,239,522 |
| 2020-06-26 | 2018 | Chandra Vargeese, Ph.D. Chief Technology Officer | 400,000 | 0 | 0 | 163,200 | 10,572 | 2,174,565 |
| 2019-06-26 | 2018 | Keith C. Regnante Chief Financial Officer | 350,000 | 0 | 0 | 142,800 | 9,060 | 1,691,020 |
| 2019-06-26 | 2018 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 541,100 | 0 | 0 | 303,557 | 9,983 | 5,839,966 |
| 2019-06-26 | 2017 | Paul B. Bolno, M.D., MBA President and Chief Executive Officer | 515,300 | 0 | 0 | 283,400 | 528 | 3,196,645 |
| 2019-06-26 | 2017 | Keith C. Regnante Chief Financial Officer | 327,400 | 0 | 0 | 144,100 | 6,136 | 761,847 |
| 2019-06-26 | 2018 | Christopher Francis, Ph.D. Senior Vice President, Corporate Development, Head of Emerging Areas | 363,000 | 0 | 0 | 129,591 | 540 | 1,682,291 |
| 2019-06-26 | 2017 | Christopher Francis, Ph.D. Senior Vice President, Corporate Development, Head of Emerging Areas | 330,000 | 0 | 0 | 127,100 | 528 | 1,103,512 |
| 2019-06-26 | 2018 | Michael Panzara, M.D., MPH Chief Medical Officer | 430,300 | 0 | 0 | 175,562 | 9,492 | 2,216,147 |
| 2019-06-26 | 2017 | Michael Panzara, M.D., MPH Chief Medical Officer | 417,800 | 0 | 0 | 183,800 | 9,342 | 1,067,001 |
| 2019-06-26 | 2018 | Chandra Vargeese, Ph.D. Senior Vice President, Drug Discovery | 400,000 | 0 | 0 | 163,200 | 10,572 | 2,174,565 |
| 2019-06-26 | 2017 | Chandra Vargeese, Ph.D. Senior Vice President, Drug Discovery | 350,000 | 0 | 0 | 154,000 | 7,380 | 1,157,264 |
| 2018-06-28 | 2017 | Chandra Vargeese, Ph.D. | 350,000 | 0 | 0 | 154,000 | 7,380 | 1,157,264 |
| 2018-06-28 | 2017 | Paul B. Bolno, M.D. President and Chief Executive Officer | 515,300 | 0 | 0 | 283,400 | 528 | 3,196,645 |
| 2018-06-28 | 2016 | Paul B. Bolno, M.D. President and Chief Executive Officer | 490,000 | 329,000 | 0 | 245,000 | 25,486 | 3,594,863 |
| 2018-06-28 | 2017 | Christopher Francis, Ph.D. | 330,000 | 0 | 0 | 127,100 | 528 | 1,103,512 |
| 2017-07-06 | 2016 | Paul B. Bolno, M.D. President and Chief Executive Officer | 490,000 | 329,000 | 0 | 245,000 | 25,486 | 3,594,863 |
| 2017-07-06 | 2015 | Paul B. Bolno, M.D. President and Chief Executive Officer | 450,000 | 112,500 | 0 | 112,500 | 397 | 3,261,615 |
| 2017-07-06 | 2016 | Michael Panzara, M.D. | 193,534 | 55,000 | 0 | 162,200 | 496 | 2,762,044 |
| 2017-07-06 | 2016 | Keith C. Regnante. | 120,000 | 0 | 0 | 48,300 | 331 | 1,639,550 |
| 2016-07-15 | 2014 | Paul B. Bolno, M.D. President and Chief Executive Officer | 450,000 | 0 | 0 | 112,500 | 71 | 562,571 |
| 2016-07-15 | 2014 | Chandra Vargeese, Ph.D. Senior Vice President, Head of Drug Discovery | 118,750 | 0 | 0 | 32,945 | 29 | 151,724 |
| 2016-07-15 | 2015 | Chandra Vargeese, Ph.D. Senior Vice President, Head of Drug Discovery | 285,000 | 71,250 | 0 | 71,250 | 397 | 1,138,322 |
| 2016-07-15 | 2014 | Christopher Francis, Ph.D. Vice President, Head of Business Development | 131,042 | 0 | 0 | 29,671 | 50 | 160,763 |
| 2016-07-15 | 2015 | Christopher Francis, Ph.D. Vice President, Head of Business Development | 185,000 | 46,250 | 0 | 46,250 | 397 | 748,626 |
| 2016-07-15 | 2015 | Paul B. Bolno, M.D. President and Chief Executive Officer | 450,000 | 112,500 | 841,986 | 112,500 | 397 | 3,261,615 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
